MODALITY
saveBi-specific T-cell engager (BiTE)
T-cell engagers redirecting T cells to tumor antigens.
also known as: bite, bispecific t-cell engager
🐶 often sniffed alongside
top 3drugs
0
catalysts
0
news
16
companies
0
Top drugs
no drugs tagged with this interest yet
🐶 Top companies
no companies tagged with this interest yet
Recent catalysts
no catalysts tagged with this interest yet
Recent news
view all →- Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engagerfiercebiotech · 4d ago
- AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trialfiercebiotech · 1mo ago
- HHS spins a tale of a would-be content creator childstat · 1mo ago
- Nearly 1/4 dealing with long-term unemployment call it quits on biopharma job searchesbiospace · 1mo ago
- CDC releases latest life expectancy datastat · 1mo ago
- Regeneron ends eye disease trial for anti-CD3 antibody following safety reviewfiercebiotech · 1mo ago
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027fiercebiotech · 2mo ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesfiercebiotech · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that